Apogee Therapeutics, Inc.

As of October 10, 2025, Apogee Therapeutics, Inc. shows a neutral trend with mixed signals, having outperformed the S&P 500 recently but with a negative one-year return.

As of October 10, 2025, Apogee Therapeutics, Inc. shows a neutral technical trend with mixed indicators, outperforming the S&P 500 recently but having a negative one-year return.

As of September 26, 2025, Apogee Therapeutics, Inc. is in a mildly bearish trend, indicated by bearish MACD, Bollinger Bands, and moving averages, with a year-to-date return of -15.63% compared to the S&P 500's 12.96%.

As of September 26, 2025, Apogee Therapeutics, Inc. shows a mildly bearish trend due to negative signals from the MACD, KST, and moving averages, with a significant underperformance of -34.15% compared to the S&P 500's 15.64% return over the past year.

As of September 26, 2025, Apogee Therapeutics, Inc. shows a mildly bearish trend due to negative indicators like a bearish MACD and underperformance of -34.15% compared to the S&P 500's 15.64% return.

As of September 19, 2025, Apogee Therapeutics, Inc. is in a bearish trend with moderate strength, indicated by a bearish MACD and KST, while underperforming the S&P 500 with year-to-date and one-year returns of -16.2% and -35.03%, respectively.

As of September 19, 2025, Apogee Therapeutics, Inc. is in a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -19.36%.

As of September 12, 2025, Apogee Therapeutics, Inc. has a bearish trend with moderate strength, indicated by a bearish MACD and moving averages, while underperforming the S&P 500 with a return of -27.95% compared to its 17.14%.

As of June 13, 2025, Apogee Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators like MACD and KST provide mixed signals, leading to overall weak sentiment.

Apogee Therapeutics, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $55 million and a market cap of $2.48 billion. The company has no dividend yield and negative return on equity.

As of Jun 18, Apogee Therapeutics, Inc. has a market capitalization of $2.48 billion, with net sales of $0.00 million and a net profit of -$205.40 million over the last four quarters. The company reported shareholder's funds of $716.79 million and total assets of $753.95 million as of Dec 24.